Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

University Compounding Pharmacy Announces Rebrand to MediVera Compounding Pharmacy™

MediVera

University Compounding Pharmacy, a leader in personalized medicine since 1999, today announced it is rebranding as MediVera Compounding Pharmacy™. The rebrand comes at a time when the company is growing strongly due to the introduction of new product offerings, nationwide expansion, and the successful differentiation of its quality products and services. Despite the name change, the company’s ownership and passionate team remain the same, ensuring continuity in the high-level service and exceptional care that healthcare providers and patients have relied on for more than two decades. Over the past few years, the company has seen its revenue grow substantially. New product offerings, nationwide expansion, and strong market positioning through differentiated quality products and services, such as the Impressed Advantage program, have enabled the company to double its revenue from 2022 to 2023. Growth is anticipated to accelerate this year, with the company expecting to double revenue year-over-year once again. “Differentiation is and will continue to be an important growth driver for our company. With the Impressed Advantage customer service program, we are making the prescription process easier, faster, and more convenient for both doctors and their patients,” said Bradley McCloskey, PharmD, CEO. “As we continue to launch more product offerings and expand into more states within the next few months, 2024 is poised to become a year of strong growth as we expand our footprint into 14 additional states.” For more information about MediVera Compounding Pharmacy and its services, please visit mediverarx.com or contact Laurie Malseed, Marketing Specialist, at laurie@mediverarx.com or 937-242-0430. About MediVera Since its inception in 1999, MediVera Compounding Pharmacy™ (formerly University Compounding Pharmacy) has been dedicated to providing personalized medicine. With a focus on quality and innovation, MediVera Compounding Pharmacy™ continues to set industry standards, offering tailored solutions to meet the unique needs of healthcare providers and patients. MediVera Compounding Pharmacy™ is currently licensed in and ships to the following 33 states: AZ, CN, CO, DE, FL, GA, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, NH, NJ, NY, OH, PA, RI, SC, SD, TN, VA, VT, WA, WI, WY. Contact Details MediVera Compounding Pharmacy Laurie Malseed +1 937-242-0430 laurie@mediverarx.com

July 16, 2024 09:00 AM Eastern Daylight Time

Ultrahuman announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Ultrahuman

Ultrahuman, a pioneer in wearable technology, launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. This is the world’s first in a smart ring form factor. Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals. At the forefront of PowerPlugs is AFib Detection, a PowerPlug that discreetly monitors your heart rhythm every night to detect signs of Atrial Fibrillation (AFib). Ultrahuman Ring AIR is the first smart ring in the world to offer AFib detection. AFib is the most common type of irregular heart rhythm or arrhythmia. It can lead to serious health complications such as stroke and heart failure, if left undetected. Individuals with potential arrhythmia episodes or a history of irregular rhythms can now track AFib closely and seek early intervention. Speaking on the launch, Mohit Kumar, Founder and CEO of Ultrahuman said “When it comes to health, one size doesn’t fit all. That’s why we built PowerPlugs for people to pick and choose what matters most for their health and wellness. Over the next few years, you could expect thousands of applications to be built on top of Ultrahuman’s comprehensive health data platform. Given our most comprehensive data stack of health markers from Ultrahuman Ring, M1 CGM, Ultrahuman Home and more to come, there’s infinite scope to build deep experiences over the next few years. Essentially, your Ultrahuman Ring will keep getting better after your purchase.” “We’re launching our first few PowerPlugs with a novel game changing capability, AFib detection. This life saving technology comes with medical approval in limited markets currently and we’re aggressively launching new markets with regulator’s approval every few weeks.” The PowerPlugs ecosystem can be accessed through the Ultrahuman App and is available in free and premium options. Circadian Rhythm Understanding the importance of aligning with natural circadian rhythms, the Ring AIR provides actionable recommendations tailored to your lifestyle. These suggestions include the optimal times to expose yourself to natural light, exercise, and wind down in the evening, aiming to enhance your energy levels, improve sleep quality, and bolster your overall health. Pregnancy Mode Pregnancy Mode adjusts health monitoring and recommendations specifically for pregnancy. It provides tailored advice on nutrition, activity levels, and health metrics that are crucial during this time. Gain insights into how to maintain your health and your baby's development, with safety and well-being as the priority. Cycle Tracking Cycle Tracking offers a comprehensive overview of your menstrual cycle phases and predicts upcoming cycles with high accuracy. This tool provides personalized insights into your fertility windows and symptom patterns, enabling proactive health management and lifestyle adjustments. Empower yourself with knowledge to make informed decisions about your reproductive health. Caffeine Window Track and optimize your consumption of stimulants such as caffeine throughout the day. By understanding your body's response to different stimulants, this tool advises on the best times for consumption to boost your alertness without affecting your nightly rest. Ideal for maintaining high energy levels and ensuring restful sleep. Vitamin D Manage Vitamin D intake through sun exposure. The app calculates the optimal times for you to step outside, based on your skin type, location, and current UV index, ensuring you get the most effective and safe sun exposure. It focuses on skin absorption, telling you precisely when to go out and estimating how much Vitamin D (in IU) your skin will absorb during your session. With real-time tracking and safety alerts to prevent overexposure, this PowerPlug makes maintaining healthy Vitamin D levels effortless and personalized. Jet Lag Jet Lag PowerPlug features personalized jet lag plans based on the users' travel itineraries, sleep patterns, and chronotypes, leveraging evidence-based methods involving light exposure, melatonin supplements, caffeine, and naps. It offers detailed schedules to follow before, during, and after trips, helping reset the circadian clock efficiently. Weight loss Integrate meal planning with real-time glucose monitoring to optimize your fitness journey. Ultrahuman Ring AIR tracks calories burnt throughout the day. It syncs with automated food logging to provide a comprehensive view of calorie intake versus expenditure. This helps users maintain a balanced diet and work towards their fitness goals without the hassle of manually logging their data. This is a game changer for anyone optimising their weight loss journey. Ovulation Women can now understand ovulation cycles, helping them better understand their bodies and menstrual health. For women looking to conceive, accurate ovulation detection can significantly increase the chances of pregnancy by identifying the most fertile days. Conversely, for those practising natural family planning methods, knowing the ovulation period can help in avoiding pregnancy. Additionally, continuous monitoring can help identify potential reproductive health issues early, allowing for timely interventions. Ultrahuman’s accessibility to health personalization doesn’t stop there. For the first time ever, developers can get access to Raw PPG, Accelerometer and Temperature data streams from the Ring AIR. Ultrahuman invites developers to build bespoke algorithms on top of these data streams from the Ring AIR using UltraSignal, Ultrahuman Ring AIR’s developer platform. UltraSignal will help fuel more customization and innovation in health. Developers can build custom algorithms for Sleep, Stress, Movement, Fertility and more, creating their own Powerplug. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. Ultrahuman’s products include the Ultrahuman M1(continuous glucose monitoring sensor), the Ultrahuman Ring and Blood Vision, a preventive blood testing platform with the pioneering UltraTrace™ technology. By collating different biomarkers, Ultrahuman is helping people improve their energy levels and lifestyle, track their workout, sleep and recovery, and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Ultrahuman Hisham Syed hisham@ultrahuman.com Company Website https://www.ultrahuman.com/

July 16, 2024 08:00 AM Eastern Daylight Time

Image

Huma completes Series D with total financing of over $80m as it launches Huma Cloud Platform with GenAI integrations to bring digital first care and research to everyone

Huma

Building and launching a scalable digital health product that meets regulatory demands typically takes a few years to deliver. Today, global healthcare AI company Huma Therapeutics Limited is announcing the completion of its Series D funding round to help cut that time down to days as it launches the Huma Cloud Platform. The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research. The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, Huma has now raised over $300m. The Series D saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others. HSBC Bank plc acted as advisor to Huma during the fundraise. Alongside its Series D, Huma is also announcing the launch of its Huma Cloud Platform – a technology ecosystem designed not only to support the company’s own digital health initiatives, but also to empower others to launch and scale their projects efficiently. With its Huma Cloud Platform and the regulatory foundation that it is built on, Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days. The Huma Cloud Platform is built to serve the company's existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb, India CDSCO Class C and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. The regulatory status of the Huma Cloud Platform significantly reduces the cost, time, and risks associated with bringing digital health projects to life. Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions. Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.” “Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can't scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.” To date, Huma’s technology has powered projects in over 3,000 hospitals and clinics. The platform has been used to engage and screen over 35 million individuals, with 1.8 million active users across its products in over 70 countries. Huma’s U.S. business has grown significantly since launch with new reimbursement codes. The RPM product, built on top of the Huma Cloud Platform for respiratory use cases, now covers 140,000 contracted lives. As a result of all these successes, the company has doubled its revenue year-on-year, and is targeting to become profitable this year. Huma also collaborates with over half of the top 20 pharmaceutical companies globally and has been involved in major national healthcare projects worldwide. Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example a feature called “10x Nurse” that significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop. This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways while keeping humans still in the loop. Looking ahead, combining the Huma Cloud Platform with next-generation AI models will enable Huma to have a bigger impact through its digital-first care and research initiatives, as well as supporting small startups and enterprises in launching the digital solutions they need. It promises to do this much faster and cheaper, shifting the focus to project or venture success rather than getting distracted with scaling technology or managing regulatory burdens. Dan Vahdat, Founder and CEO of Huma, said, “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.” About Huma Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies. Huma's technology powers: ● multi-channel patient engagement at population-wide scale for healthcare systems ● remote patient monitoring (RPM) at scale ● companion apps to support patients through treatment and drug therapies ● digital clinical trials, including decentralised trials, to accelerate medical research Huma's regulated Software as a Medical Device, used in its RPM and companion app platforms, is the only disease- and device- agnostic platform to hold EU MDR Class IIb, US FDA (510-k) Class II clearance and Class IIb registration with the UK MHRA. The SaMD platform is regulated to accept artificial intelligence algorithms and monitor patients of all ages. For more information please visit www.huma.com. Contact Details Huma Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.huma.com/

July 16, 2024 08:00 AM Eastern Daylight Time

Image

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a cutting-edge medical technology company developing targeted nerve therapies to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated. The company's ongoing proof-of-concept (PoC) human clinical trial is evaluating the safety and efficacy of radiofrequency (RF) ablation in a transvascular approach to reduce pain associated with pancreatic cancer and, to date, has demonstrated extremely compelling results. If successful, Autonomix has the potential to dramatically impact patient well-being and improve quality of life, offering new hope for patients enduring pancreatic cancer pain. Key Trial Insights The initial phase of the clinical trial involved five lead in patients who underwent the procedure without complications or significant adverse events. Some 60% of these subjects experienced a significant reduction in pain, with a mean decrease of 6.33 points on the Visual Analogue Scale (VAS) pain scale, dropping from a baseline of 8.0 to 1.67 just seven days post-procedure. Patients also reported quick pain relief, with some feeling better as soon as one day after the procedure. A detailed look at the data should provide Autonomix with important insight into optimizing the procedure, particularly the catheter entry point, where three of the five patients who benefited with meaningful pain reduction had femoral access to the catheter and the two that did not respond had brachial access. The primary objective of this PoC trial is to assess the success rate of ablating relevant nerves to mitigate pain in patients with pancreatic cancer using radiofrequency ablation. Secondary objectives include evaluating device- and procedure-related adverse events up to six weeks post-procedure, changes in pain levels and improvements in quality of life from pre- to post-procedure. Autonomix is proceeding with enrolling an additional 20 subjects to participate in the study and expects to complete enrollment by the end of 2024. The company expects to report topline results from all 20 subjects in the first half of next year. Clinical Trial Testimonials According to Autonomix, patients in the responder group reported substantial improvements in their quality of life. On average, these patients noted a 78% enhancement in how they viewed their overall health and a 45% boost in how they viewed their life quality, within seven days of the procedure. This rapid relief is crucial for individuals facing end-of-life situations due to advanced pancreatic cancer, offering them a better quality of life during their remaining time. Patient testimonial s further emphasize the impact of the procedure. Before the procedure, patients can struggle with debilitating pain, which affects their ability to sleep, eat and perform daily activities. Post-procedure, patients experienced immediate, life-changing pain relief and could sleep on their back, return to work and attend social events. Additionally, one patient stated they no longer needed painkillers, and experienced significant improvements in overall health and quality of life. This transformation underscores the procedure's potential to greatly enhance the lives of patients suffering from pancreatic cancer pain. Technical Approach And Future Plans Autonomix's technology aims to improve upon current pain management methods, which often rely on systemic drugs like opioids or invasive procedures that can have severe side effects. Autonomix’s catheter-based system is also designed to detect and ablate pain-associated neural signals more accurately. While the current trial focuses on pancreatic cancer-related pain, Autonomix also plans to explore other indications in the future based on these promising results. A New Dawn In Pain Management Autonomix’s innovative approach to pain management for pancreatic cancer patients is showing encouraging potential. The initial success of its PoC clinical trial offers a glimpse into a possible future where patients suffering from severe pain can find relief through precise and effective medical technology. As the company gathers more data, the medical community awaits its results, which could revolutionize pain management far beyond just pancreatic cancer pain and have applications across all pain and diseases of the peripheral nervous system. Featured photo by Alexander Grey on Unsplash Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

July 12, 2024 08:45 AM Eastern Daylight Time

Image

Nevis Brands CEO Announces Strong Q2 Financial Results and Growth Plans

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the company's financial results for the second quarter, ending May 31st, 2024. Nevis reported cannabis beverage royalty revenues totaling $436,532, with a Cost of Goods Sold amounting to $145,170 and a Gross Profit of $291,392. This performance marks a 15 percent increase over revenues from the previous quarter. Kueber expressed his satisfaction with the company's growing revenues and positive EBITDA. He highlighted the ongoing expansion of Nevis's presence in active states, the development of their product line, and the increasing number of dispensaries selling Nevis products. According to Kueber, Q2 revenues were generated from sales in Washington, Oregon, California, Nevada, Colorado, Arizona, Ohio, and Missouri. He also mentioned that Michigan and Mississippi are still in pre-production phases and are expected to contribute to revenues in the third quarter. Looking ahead, Kueber emphasized Nevis's commitment to innovation, with plans to introduce new products to existing markets in 2024, ensuring the company continues to capture market share and drive growth. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

July 11, 2024 10:13 AM Eastern Daylight Time

Video

Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs

Superlab Suisse

For life sciences and biotech companies, access to affordable dedicated lab spaces is hard to come by. Labs are prohibitively expensive to build and operate, posing significant financial barriers to innovation and research. A cutting-edge new alternative is being offered by Superlab Suisse, a leading provider of innovative laboratory and research spaces that today announces the grand opening of its newest facility in Basel. With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. Opening in July 2024, following the success of the Lausanne location supported by Biopôle Lausanne and InnoVaud, the expansion marks a significant milestone in Superlab Suisse's mission to provide research infrastructure to Switzerland's dynamic life sciences sector. Forging ahead with its successful partnership with Swiss Prime Site, Superlab Suisse is set to open the door for huge commercial opportunities in the ideally suited location of Basel, a booming biotechnology hub and home to over 700 companies including pharmaceutical giants like Novartis and Roche. The new facility, nestled within the bustling Stücki Park with neighbours like Tech Park Basel, Lonza, Medartis, NBE, and Boehringer Ingelheim, offers ready-to-use laboratory spaces equipped with the latest technology and essential operational support services, allowing teams to channel their resources into scientific research rather than lab operations. Spanning over 4770 square metres, it promises to be a nucleus of scientific collaboration and breakthrough, redefining laboratory services in Basel. "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma," says Xi Zhang, CEO of Superlab Suisse. “Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover”. Life sciences and biotech companies have until now lacked the widely accepted lab solutions that have benefitted industries such as tech and finance. Universities have typically been the only viable option, with lab construction and operation requiring significant upfront investments — costs which redirect attention away from research and delay progress in getting products to market. Superlab Suisse's serviced BSL1 and BSL2 labs provide a new industry standard of lab solution. Users in one location such as Basel also gain access to facilities in Lausanne and other locations. By delivering ready to move in lab solutions for life science companies of all sizes, including startups, scale-ups, and corporates, Superlab Suisse eliminates the hurdles of lab construction and operation. One of the first companies to secure their space at the opening is Skyhawk Therapeutics, which has recently announced a research collaboration with Ipsen focusing on RNA targeting in rare neurological diseases. In addition to the Basel location, Superlab Suisse continues its commitment to innovation with plans for a third site in Zurich Schlieren. This new facility, scheduled to open in March 2025, will cater to the diverse needs of start-ups, spin-offs, and established companies in the life sciences sector, further solidifying Superlab Suisse's position as a leader in laboratory-as-a-service solutions. This one-stop solution not only solves the true problems of life science companies but also attracts like-minded innovators to meet and collaborate. Superlab is expanding this year to more cities in Europe, the US, and Asia, embodying a borderless lab concept because life science benefits humanity as a whole. Dr. Rajwinder Lehal, CEO of biotech business Cellestia commented: “Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation. Superlab provided us with state of the art infrastructure and equipment that we needed to hit the ground running from day 1.” Emmanuel Savioz, CEO & Chairman, Tigen Pharma commented: “Superlab is a great place to work in a vibrant scientific community. Our team at Tigen can focus on growth, supported by state-of-the-art facilities, latest equipment and a competent and fun Superlab team to support on-site”. About Superlab Suisse AG Superlab Suisse AG offers innovative laboratory solutions through its "Lab as a Service" business concept. With state-of-the-art facilities, professional services, and financing support, Superlab Suisse empowers companies in the biotech, pharma, and medtech sectors to focus on research and innovation. About Swiss Prime Site AG Swiss Prime Site is the largest real estate company in Switzerland and one of the leading commercial property companies in Europe. The real estate portfolio spanning across densely populated areas is valued at approximately CHF 26 billion and includes own properties – with about CHF13 billion commercial properties and development projects – as well as ones managed on behalf of third parties with about CHF 13 billion AuMs invested in residential and commercial buildings. Contact Details Superlab Suisse Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://superlabsuisse.com/

June 25, 2024 07:00 AM Eastern Daylight Time

Image

Botanical Remedies LLC Introduces Enhanced Kratom Feature for Customized Potency

Rev Up Marketers

Botanical Remedies LLC, a leading provider of premium, lab-tested kratom products, is proud to announce the launch of its innovative Enhanced Kratom Feature, designed to offer customers a tailored experience with customized potency. This new feature marks a significant advancement in the kratom industry, underscoring the company's commitment to quality, safety, and customer satisfaction. The Enhanced Kratom Feature allows customers to select kratom products with customized potency levels, catering to individual preferences and needs. This feature leverages advanced processing techniques and rigorous lab testing to ensure each product meets precise potency specifications. By offering customizable options, it empowers users to fine-tune their kratom experience for optimal wellness benefits. Botanical Remedies LLC is dedicated to providing the highest-quality kratom products. The company meticulously sources its kratom from reputable farmers and suppliers who prioritize ethical practices and sustainability. Each batch of kratom undergoes rigorous third-party testing to verify its purity, potency, and safety. This comprehensive testing process ensures that products are free from contaminants, heavy metals, and adulterants, offering customers peace of mind and a superior product. The Enhanced Kratom Feature is available across Botanical Remedies LLC’s extensive range of kratom strains, including popular varieties such as Green Maeng Da, Gold Vein, and Hippie Dip. Customers can now choose their preferred strain and customize the potency to match their specific requirements. Whether seeking relaxation, focus, or energy, users can select the precise potency that best suits their needs. Ordering from Botanical Remedies LLC, is a seamless process. Customers can browse the extensive collection of premium kratom products on the company’s website, select their preferred strain and potency, and proceed to a secure checkout. The company prioritizes the safety of customer information, ensuring a secure transaction process. The company ensures prompt and discreet delivery of orders through fast and discreet shipping. Botanical Remedies LLC prides itself on providing exceptional customer support. The knowledgeable and friendly team is available to assist with any questions or concerns, offering guidance on product selection and usage. The company is committed to ensuring customer satisfaction and building long-lasting relationships with its valued clients. Confident in the quality of its products, Botanical Remedies LLC offers a satisfaction guarantee. If customers are not entirely pleased with their purchase, the company’s customer service team will work diligently to resolve any issues and ensure complete satisfaction. Customers who choose Botanical Remedies LLC join a thriving community of kratom enthusiasts. The company engages with its community through social media and newsletters, providing updates on new products, exclusive offers, and kratom-related information. About Botanical Remedies LLC is a veteran-owned company dedicated to providing premium, lab-tested kratom products. The company combines its dedication to quality with a profound respect for ethical practices, guaranteeing the sustainable sourcing and rigorous testing of all products. With a focus on customer satisfaction, it continues to set the standard in the kratom industry. For more information about Botanical Remedies LLC and the Enhanced Kratom Feature, please visit www.botanicalremediesllc.com. Contact Details Botanical Remedies LLC Shelly Hughes +1 305-393-4847 support@bremediesllc.com Company Website http://www.botanicalremediesllc.com/

June 24, 2024 10:13 AM Eastern Daylight Time

Image

Roberts & Ryan Inc. expands its internship program in partnership with the Boys and Girls Club of Harlem.

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned (SDVO) broker-dealer, announced the expansion of its summer internship program, which recently accepted 13 candidates from a diverse pool of students from a variety of schools and backgrounds. The expansion reflects the company’s commitment to supporting veterans and underprivileged youth. “At Roberts & Ryan, we believe that supporting future generations of financial professionals is important to the long-term success of our industry. This year’s internship class was bolstered by our relationship with the Boys & Girls Club of Harlem, who recommended two exceptional candidates, creating more opportunities for diverse talent in the financial services industry,” said Brian Rathjen, President of Roberts & Ryan. Seven interns completed Roberts & Ryan's internship program in 2023, a number the firm nearly doubled in 2024 due to increased student demand. Roberts & Ryan runs two internship cohorts per year to provide students from a variety of backgrounds with real-world experience in the financial services industry. Interns collaborate with experienced professionals on projects that demonstrate a range of services provided by Roberts & Ryan, from secondary equity and fixed income trading to debt and equity capital markets, business development, compliance, and marketing. Roberts & Ryan was recently approved for membership by the New York Stock Exchange, and summer interns have access to its iconic trading floor. "Breaking into the financial services industry can be a challenge, as most entry-level positions require either previous work experience or a professional connection with someone in the industry. We believe that our program provides our interns with both,” said Edward D’Alessandro, Chief Executive Officer of Roberts & Ryan. Roberts & Ryan is committed to increasing access to opportunities in the financial sector by finding high-quality candidates for their internship program. Through the program, interns gain valuable experience, make important connections, and build a talent stack for a successful career in finance. For current undergraduate and graduate students interested in participating in next year’s internship program, please email your resume to info@roberts-ryan.com. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

June 13, 2024 09:00 AM Eastern Daylight Time

Image

Stupid Cancer Announces CancerCon Live 2024 in Austin, Texas

Stupid Cancer

Stupid Cancer, the leading nonprofit organization dedicated to empowering everyone affected by adolescent and young adult (AYA) cancer, is thrilled to announce that CancerCon Live 2024 will take place in Austin, Texas for the first time ever. This landmark event, scheduled for August 15 - 18, 2024 at the Hyatt Regency Austin, promises to bring together hundreds of young adult cancer patients, survivors, caregivers, and advocates from across the country to share their experiences, gain valuable insights/resources, and build lasting connections. “We look forward to creating an unforgettable experience that empowers young adults affected by cancer and helps them connect with others who truly understand their journey.” says Alison Silberman, CEO of Stupid Cancer. CancerCon Live is the premier annual gathering for the AYA cancer community, offering a unique blend of education, support, and empowerment. This year's event in Austin will feature: Keynote Speakers: Hear from leading voices in the AYA cancer community, including survivors, healthcare professionals, and advocates, sharing their stories and insights on topics ranging from advancements in cancer treatment to survivorship challenges. Workshops and Panels: Participate in interactive sessions on a wide range of topics tailored to the unique needs of AYA cancer patients, survivors, and caregivers, covering mental health, fertility preservation, advocacy, career development, and more. Meet the AYA Community: Dedicated time for attendees to connect with peers, build lasting friendships, and expand their support networks in a supportive and inclusive environment. Exhibit Hall: Explore resources, products, and services from leading organizations committed to supporting the AYA cancer community as well as a few local small businesses. Social Events: Enjoy fun and engaging social activities designed to foster connections and create memorable experiences with some local Austin flavor. Local excursions: Attendees will have the opportunity to explore the city’s unique attractions, including Bat Watching under Congress Bridge and unlimited Skee-Ball at Full Circle Bar, to name a few, all while engaging in meaningful activities that support their personal and collective growth. “Austin’s dynamic and inclusive culture aligns perfectly with our mission to build a strong, supportive community for AYA cancer patients and survivors. We look forward to welcoming everyone to what promises to be our most impactful CancerCon yet,” says Eddie Mouradian, Director of Development. For over a decade, Stupid Cancer has brought together hundreds of patients, survivors, caregivers, advocates, and health professionals at the largest gathering of the AYA community - CancerCon (R). Now gathering both online and off, every CancerCon event is an immersive experience, led by transformative connection and education. The majority of conference attendees are AYA (age 15-39) cancer patients and survivors, but caregivers and health professionals of all ages are also welcome. CancerCon Live is hosted in a different US city each year as we seek to make the event always be within reach of our community at all times. Registration for CancerCon Live 2024 is now open. To register or learn more about the event, please visit cancercon.org. About Stupid Cancer Stupid Cancer’s mission is to help empower everyone affected by adolescent and young adult cancer by ending isolation and building community. Through innovative programming and strategic communications, the organization aims to provide support, resources, education, and a sense of community both online and in-person. For more information, please visit stupidcancer.org. For media inquires, contact: media@stupidcancer.org About Stupid Cancer:Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Contact Details Alison Silberman +1 646-868-0087 media@stupidcancer.org Company Website https://stupidcancer.org/

June 12, 2024 02:39 PM Eastern Daylight Time

Image

1 2 3 4 5 ... 108

Back